Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4203 Comments
1887 Likes
1
Glika
Power User
2 hours ago
So late… oof. 😅
👍 170
Reply
2
Aarohi
Consistent User
5 hours ago
Exceptional attention to detail.
👍 65
Reply
3
Khyel
Legendary User
1 day ago
Volume is concentrated in certain sectors, reflecting shifting investor priorities.
👍 165
Reply
4
Ethanpaul
Regular Reader
1 day ago
This feels like step 100 already.
👍 219
Reply
5
Ricaria
Insight Reader
2 days ago
I need to find others who feel this way.
👍 281
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.